

Special Issue

Neurofibromatosis Type 1 (NF1) Related Tumors (2nd Edition)

Message from the Guest Editors

This Special Issue is a continuation of our previous Special Issue, “Neurofibromatosis Type 1 (NF1) Related Tumors”

(https://www.mdpi.com/journal/cancers/special_issues/MKJGT4K1HG).

Neurofibromatosis Type 1 (NF1) is a cancer predisposition syndrome, with afflicted patients developing benign and/or malignant tumors at distinct developmental stages. The pathognomonic feature is the development of nerve sheath tumors, cutaneous neurofibromas, and plexiform neurofibromas, with the latter capable of transformation into malignant peripheral nerve sheath tumor (MPNST), an incurable sarcoma with metastatic potential. In this Special Issue, we aim to summarize, explore, and characterize the features of NF1-related tumors, covering both basic and (pre)clinical aspects to advance our understanding of targeting these complex diseases. We look forward to receiving your contributions.

Guest Editors

Dr. Daochun Sun

Department of Cell Biology, Neurobiology and Anatomy, The Medical College of Wisconsin, Milwaukee, WI 53226, USA

Dr. Sameer Farouk Sait

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/243303

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)